Bristol-Myers Squibb Company (BMY) 65.80

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bristol-Myers Squibb Company (BMY) 65.80 $BMY

Bristol-Myers presents data on daclatasvir at Liver Meeting
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 6:30PM CDT

GILD: 103.69 (-1.52), BMY: 65.80 (-0.20)

Preliminary data show 100% SVR4 for Viekirax + Exviera
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 4:48PM CDT

GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20), ENTA: 37.14 (+0.56)

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Apr 24, 7:21PM CDT
There are still plenty of companies doing well this quarter and investors need to take advantage of the opportunities when they see them, Cramer says.
GRUB: 46.00 (-0.25), XOM: 86.97 (-0.57), KRFT: 87.57 (-0.81), UPS: 98.10 (-0.12), SBUX: 51.84 (+2.41), SAVE: 77.42 (+0.43), IBM: 169.78 (-0.46), GOOGL: 573.66 (+16.20), SIX: 51.08 (+1.20), TMUS: 34.31 (-0.13), TWTR: 50.82 (-0.59), CBSH: 42.67 (-0.10), MSFT: 47.87 (+4.53), AAPL: 130.28 (+0.61), WFM: 49.63 (+1.38), AMZN: 445.10 (+55.11), FTR: 7.03 (-0.04), SEAS: 21.49 (+0.35), COLM: 62.84 (+0.73), FCAU: 16.19 (+0.11), BMY: 65.80 (-0.20), MAR: 81.84 (+0.49), CLB: 124.69 (-0.63), NFLX: 558.40 (-0.66), RDS.A: 62.76 (-0.20), QLIK: 35.30 (+1.65), CVS: 101.58 (+0.70), CVX: 109.87 (-0.10)

Final Glance: Pharmaceuticals companies
AP - Fri Apr 24, 7:08PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 101.08 (+0.62), BAX: 71.14 (-0.37), PFE: 35.27 (-0.09), BMY: 65.80 (-0.20)

Midday Glance: Pharmaceuticals companies
AP - Fri Apr 24, 12:36PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 101.08 (+0.62), BAX: 71.14 (-0.37), PFE: 35.27 (-0.09), BMY: 65.80 (-0.20)

Early Glance: Pharmaceuticals companies
AP - Fri Apr 24, 9:55AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 101.08 (+0.62), BAX: 71.14 (-0.37), PFE: 35.27 (-0.09), BMY: 65.80 (-0.20)

Bristol-Myers may be mulling bid for Celgene
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 9:27AM CDT

BMY: 65.80 (-0.20), CELG: 118.71 (+2.62)

European Ad Comm backs Bristol-Myers' Opdivo for melanoma
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 9:14AM CDT

BMY: 65.80 (-0.20)

Merck's HCV combo shows cure rates of 60 - 100% in three genotypes
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 8:05AM CDT

JNJ: 101.08 (+0.62), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20)

Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Business Wire - Fri Apr 24, 6:46AM CDT
--Opinion based on superior survival benefit demonstrated from CheckMate -066 trial in first-line patients and improved response rate in CheckMate -037 study in previously treated patients
BMY: 65.80 (-0.20)

Will Biogen's (BIIB) Earnings Streak Continue in 1Q? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Apr 23, 3:57PM CDT
Investor focus this quarter will remain on the performance of Biogen's (BIIB) oral MS treatment, Tecfidera.
BIIB: 401.71 (-28.57), UTHR: 186.69 (-1.87), TEVA: 64.41 (+1.16), BMY: 65.80 (-0.20)

A Discussion Of Amgen's Q1 Results, With Updates On Its Pipeline
DoctoRx - at Seeking Alpha - Wed Apr 22, 8:28AM CDT

PFE: 35.27 (-0.09), AMGN: 167.91 (-1.26), LLY: 71.58 (-0.82), BMY: 65.80 (-0.20), SNY: 51.75 (-0.01), REGN: 480.09 (+0.01), HSP: 87.61 (-0.05), CELG: 118.71 (+2.62)

Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:11AM CDT
Biotechnology is rapidly giving rise to ground-breaking new medicines that are dramatically changing the outlook for devastating diseases such as hepatitis C, malaria, and, perhaps most astoundingly, cancer. This innovation boom has gone hand in hand...
AGEN: 7.12 (+0.75), ADXS: 23.34 (-0.27), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), BMY: 65.80 (-0.20), FPRX: 24.20 (-0.26)

Clopidogrel Bisulfate Market 2015-2020 Research Reviews
PR Newswire - Wed Apr 22, 7:00AM CDT
DeepResearchReports.com have "2015 Market Report on Global Clopidogrel Bisulfate Industry" added to its research database. The report spread across 159 pages and available for ready purchase priced at the single user pdf (USD 2600).
BMY: 65.80 (-0.20)

Healthcare's Health Scanner: Complementary Research on Pfizer, Mylan, Teva Pharmaceutical, Bristol-Myers Squibb, and Merck & Company
PR Newswire - Wed Apr 22, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MRK: 57.60 (+0.09), PFE: 35.27 (-0.09), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), BMY: 65.80 (-0.20)

Exelixis on Path to Beat Estimates; Analyst Brief Issued by BrokerBank Securities, Inc.
PR Newswire - Wed Apr 22, 6:00AM CDT
Exelixis, Inc. (NASDAQ: EXEL) a San Francisco based biotechnology company is set to announce its latest earnings results on April 30, 2015. With recent revisions of earnings estimates, investors are watching to see this darling continue to perform. Exelixis has appreciated significantly since the start of 2015 and growth is expected to continue. Seeing favorable results on its leading compound from the FDA drives the idea of future growth potential.
MRK: 57.60 (+0.09), BMY: 65.80 (-0.20), EXEL: 3.08 (-0.02)

Seattle Genetics' Adcetris Under Review for New Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:07PM CDT
Seattle Genetics, Inc.'s (SGEN) supplemental BLA for Adcetris has been accepted by the FDA for priority review as consolidation therapy in the post-transplant setting.
SGEN: 37.14 (-0.36), SHPG: 255.11 (-0.26), HZNP: 31.75 (+0.97), BMY: 65.80 (-0.20)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AEVEX Facing Class Action: Deadline Looms for Investors

Updated Category News Views 15

The Clock is Ticking for AVEX Investors News flash, folks: If you bought into AEVEX Corp. (NYSE: AVEX) between mid-April and early June this year, you might have a legal gold mine on your hands—or at least a shot to join a class action that could knock some dollars back into your pocket. Mark it on your calendar—October 20, 2026, is the last call to toss your hat in...

Continue Reading
Tumor Ablation Market: Charting a Billion-Dollar Surge

Updated Category News Views 1

Cancer's Unforgiving Climb: Opportunity Amidst Challenge Looking at the current state of the global tumor ablation market, one thing's clear—it's on a sort of upward swing you'd expect trains to make, riding the rails of rising cancer rates and technological advancements. At least that's what the folks at Wissen Research are banking on, projecting a leap to $1.8 billion...

Continue Reading
Richard Huffman Joins IFA Board, Strengthens Franchise Ties

Updated Category News Views 11

Ever wonder how the cogs in this massive machine called franchising keep turning? It's folks like Richard Huffman who step up to the plate, and his recent election to the International Franchise Association (IFA) Board of Directors is worth a second glance. Huffman: A Franchise Veteran Now, Huffman isn't some rookie in the world of franchising. You see, back in '94, he...

Continue Reading
Florida Cancer Center Expands Expertise with New Oncologist

Updated Category News Views 7

Welcoming a Highly Skilled Oncologist to Fort Myers There's an old saying in the world of investing: follow the expertise. And when it comes to healthcare, especially cancer treatment, expertise can make a world of difference. Florida Cancer Specialists & Research Institute (FCS) is throwing its hat in the ring with authority, as they welcome Dr. Kelly Elleson, a surgical...

Continue Reading
Zika Virus: A Surprising Ally in Brain Cancer Fight

Updated Category News Views 1

Here’s something you don’t hear every day: using a virus that typically targets the brain not as a foe, but as a formidable ally in the war against glioblastoma. It’s a gutsy play by UP Oncolytics, a scrappy biotech outfit cradled within Rosalind Franklin University’s Helix 51 incubator. Risky Bet on a Known Adversary Glioblastoma—a real beast in the cancer...

Continue Reading
ASTS Fraud Lawsuit: Investors' Chance to Step Up

Updated Category News Views 1

Investors Grapple with AST SpaceMobile's Legal Challenges When I hear 'securities fraud lawsuit,' my gut instinct as a trader is to dig deep into the grime and figure out what's lurking beneath. AST SpaceMobile, those folks aiming to shake up the satellite game, have some explaining to do. If you've been holding onto ASTS shares between March 4, 2025, and July 15, 2026,...

Continue Reading
Moore Law Urges Millrose Investors: Join the Action

Updated Category News Views 3

Is Millrose Playing a Risky Game? When I caught wind of this latest debacle with Millrose Properties, Inc. (NYSE: MRP), my gut reaction was a mix of curiosity and skepticism. Hunterbrook Media's report just blasted across the headlines, digging up some dirt on Millrose's recent financial maneuvers. Apparently, these cats have been busy buying homes to the tune of $200...

Continue Reading
Ball Corp's Leadership Shuffle Aims for Strategic Gains

Updated Category News Views 0

Leadership Changes in the Midst of Market Challenges You don't need a crystal ball to see that leadership changes can signal either turmoil or opportunity. Ball Corporation, a titan in the realm of aluminum packaging, is experiencing a shake-up at the top of its beverage packaging business units. With Carey Causey stepping into the role for North and Central America, and...

Continue Reading
New Chapter Recovery Garners Key Accreditations

Updated Category News Views 7

Accreditations That Matter It's not every day a treatment facility pops its head up with credentials that weigh like a ton of bricks. New Chapter Recovery in New Jersey just snagged two heavy hitters: Joint Commission accreditation and LegitScript certification. These badges don’t just glimmer for show; they’re the market's assurance against empty promises—an...

Continue Reading
Ruth E. Carter Returns Home with Celebrated Exhibition

Updated Category News Views 2

Ruth E. Carter’s Triumphant Return When a titan of the costume design world circles back to their roots, you know it’s bound to be something special. Ruth E. Carter, who has swapped needles and threads for Oscars (twice, mind you), is making a return to Hampton University, paying homage to the very soil that sowed her artistic seeds. Ain't that a capstone of a career...

Continue Reading

Top 5 Most Recently Viewed Articles

Raytron's Next-Gen Thermal Imaging Revolutionizes Night Vision

Updated Category News Views 139

Raytron's Innovation in Thermal Imaging Technology In today's world, the demand for reliable solutions to monitor conditions during the night is at an all-time high. With applications in industries such as automotive, security, and environmental conservation, the need for advanced thermal imaging technology is crucial. Raytron, recognized as a frontrunner in infrared...

Continue Reading
Zeo Energy Corp's Strategic Acquisition Enhances Clean Energy Vision

Updated Category News Views 300

Zeo Energy Corp's Strategic Acquisition Enhances Clean Energy Vision Acquisition Aims to Merge Solar Power with Advanced Storage Techniques Transaction Signals a Significant Step towards a Comprehensive Clean Energy Platform Zeo Energy Corp (Nasdaq: ZEO), a prominent provider of solar energy and energy efficiency solutions based in Florida, has made headlines again with...

Continue Reading
Automotive Bushing Market Expected to Exceed $264 Billion

Updated Category News Views 140

Automotive Bushing Market Overview The Automotive Bushing Market is anticipated to reach USD 264.30 billion by 2032, experiencing a compound annual growth rate (CAGR) of 5.14% from 2024 to 2032. This growth is largely attributed to the rising demand for higher-end vehicles in emerging markets. As consumers increasingly seek comfort and performance, there is a noticeable...

Continue Reading
Investigation on Semler Scientific Securities: What You Need to Know

Updated Category News Views 243

Investigation of Semler Scientific, Inc. Securities The Rosen Law Firm, renowned for protecting investor rights, is currently engaged in an investigation involving Semler Scientific, Inc., known by its ticker symbol NASDAQ: SMLR. The investigation has arisen amid allegations that the company might have conveyed materially misleading information, impacting investors'...

Continue Reading
TrustArc Unveils Arc: A Revolutionary AI Privacy Solution

Updated Category News Views 117

Revolutionizing Privacy Management with Arc In today's complex regulatory landscape, companies face unique challenges regarding compliance and privacy management. TrustArc has taken a significant step with the introduction of Arc, a state-of-the-art platform designed to help organizations navigate these challenges efficiently. Introducing Arc: The Future of Compliance...

Continue Reading